Sotorasib
- Generic Name
- Sotorasib
- Brand Names
- Lumakras, Lumykras
- Drug Type
- Small Molecule
- Chemical Formula
- C30H30F2N6O3
- CAS Number
- 2252403-56-6
- Unique Ingredient Identifier
- 2B2VM6UC8G
- Background
Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS mutations. Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s. It is the first expe...
- Indication
Sotorasib is indicated in the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who have received at least one prior systemic therapy.
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 146
- Registration Number
- NCT05327491
- Locations
- πΊπΈ
Labcorp Clinical Research Unit - Dallas, Dallas, Texas, United States
πΊπΈMiami Research Associates LLC - Main Campus / Late Phase, South Miami, Florida, United States
πΊπΈLabcorp Clinical Research Unit - Daytona Beach, Daytona Beach, Florida, United States
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities
- Conditions
- Interventions
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Vestre Viken Hospital Trust
- Target Recruit Count
- 100
- Registration Number
- NCT05311709
- Locations
- π³π΄
Vestre Viken Health Trust, Drammen, Viken, Norway
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Devalingam Mahalingam
- Registration Number
- NCT05251038
- Locations
- πΊπΈ
Northwestern University, Chicago, Illinois, United States
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 160
- Registration Number
- NCT05198934
- Locations
- π―π΅
Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan
πΊπΈKelsey Research Foundation, Houston, Texas, United States
πΊπΈNorthwest Georgia Oncology Centers PC, Marietta, Georgia, United States
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
- Conditions
- Interventions
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT05054725
- Locations
- πΊπΈ
Florida Cancer Specialists, Fort Myers, Florida, United States
πΊπΈBRCR Medical Center Inc., Plantation, Florida, United States
πΊπΈHematology Oncology Clinic, Baton Rouge, Louisiana, United States
A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy Participants
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 145
- Registration Number
- NCT05048784
- Locations
- πΊπΈ
Covance Clinical Research Unit, Dallas, Texas, United States
Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 13
- Registration Number
- NCT05045638
- Locations
- πΊπΈ
Covance Clinical Research Unit - Daytona Beach, Daytona Beach, Florida, United States
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Erasca, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04959981
- Locations
- πΊπΈ
Hackensack University Medical Center (John Theurer Cancer Center), Hackensack, New Jersey, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈDana Farber Research Institute, Boston, Massachusetts, United States
A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 42
- Registration Number
- NCT04933695
- Locations
- πΊπΈ
Texas Oncology-Dallas Presbyterian Hospital, Dallas, Texas, United States
πΊπΈRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
πΊπΈNorthport Veterans Affairs Medical Center, Northport, New York, United States
A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 173
- Registration Number
- NCT04892017
- Locations
- πΊπΈ
Siteman Cancer Center, Saint Louis, Missouri, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈRutgers Cancer Institute, New Brunswick, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.